Yingen Luo
Overview
Explore the profile of Yingen Luo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Miao L, Che Y, Tian P, Li J, Peng Q, et al.
Quant Imaging Med Surg
. 2025 Jan;
15(1):395-403.
PMID: 39839047
Background: Accurate localization of small pulmonary nodules (SPNs) during video-assisted thoracoscopic surgery (VATS) is challenging due to the small size and deep location. Both the 4-hook wire technique and methylene...
2.
Zhao H, Zhang X, Tian P, Luo Y, Sun W, Li Y, et al.
BMJ Open
. 2024 Dec;
14(12):e080805.
PMID: 39645249
Introduction: The exact role of hepatic arterial infusion chemotherapy (HAIC) in advanced hepatocellular carcinoma (aHCC) is still unknown. The combination of HAIC and sorafenib has been proven to be more...
3.
Kang W, Tang P, Luo Y, Lian Q, Zhou X, Ren J, et al.
Acad Radiol
. 2024 Nov;
PMID: 39609145
Rationale And Objectives: To develop and validate multiple machine learning predictive models incorporating clinical features and pretreatment multiparametric magnetic resonance imaging (MRI) radiomic features for predicting treatment response to transarterial...
4.
Zhao H, Li Y, Tian P, Sun W, Luo Y, Zhang X, et al.
Cancer Med
. 2024 Aug;
13(15):e70068.
PMID: 39119737
Background: The efficacy of coronavirus disease 2019 (COVID-19) vaccines in preventing SARS-CoV-2 infection in patients with hepatocellular carcinoma (HCC) is not clear. Methods: From January 2022 to October 2022, patients...
5.
Luo Y, Kang W, Tan F, Li X
J Vasc Surg Venous Lymphat Disord
. 2024 Jul;
13(1):101942.
PMID: 38950732
No abstract available.
6.
Kang W, Fu H, Luo Y, Noreika D, Cong T, Li H, et al.
J Gastrointest Oncol
. 2024 May;
15(2):780-787.
PMID: 38756648
Background: Immunotherapy has reshaped the systemic treatment of hepatocellular carcinoma (HCC), with atezolizumab plus bevacizumab (TA) regimen and regorafenib being the first-line and second-line treatment options for advanced HCC, respectively....
7.
Kang W, Xi J, Luo Y, Yang Z
Asian J Surg
. 2024 May;
47(9):4039-4041.
PMID: 38724350
No abstract available.
8.
Yang H, Cong T, Luo Y, Yang C, Ren J, Li X
J Hepatocell Carcinoma
. 2024 Jan;
11:175-189.
PMID: 38283695
Objective: To investigated the association between sarcopenia and the prognosis and adverse events of hepatocellular carcinoma (HCC) patients undergoing interventional therapy combined with immunotherapy and targeted therapy. Methods: Between January...
9.
Cong T, Yang C, Cao Q, Ren J, Luo Y, Yuan P, et al.
J Hepatocell Carcinoma
. 2024 Jan;
11:95-111.
PMID: 38250306
Purpose: Transarterial chemoembolization (TACE) represents a significant therapeutic modality for hepatocellular carcinoma (HCC). We aimed to develop a gene signature to accurately predict patient TACE response and explore the underlying...
10.
Kang W, Qiu X, Luo Y, Luo J, Liu Y, Xi J, et al.
J Transl Med
. 2023 Sep;
21(1):598.
PMID: 37674169
The advent of immunotherapy, a groundbreaking advancement in cancer treatment, has given rise to the prominence of the tumor microenvironment (TME) as a critical area of research. The clinical implications...